SPAC bust: ARCH, Deerfield and Section 32 cancel their $200M life sciences bet
A life sciences SPAC backed by industry investors Section 32, Deerfield Management and ARCH Venture Partners is closing shop well after the blank-check fad ended …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.